Korean pharma scandal deepens after disclosure in ICC case
Credit: iStock/PeopleImages
A scandal in Korea over the mislabelling of a gene therapy treatment for osteoarthritis has intensified after it emerged in an ICC arbitration that the product’s developer was allegedly aware two years ago that its ingredients had changed.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Upgrade now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10